Larimar Therapeutics, Inc. will host a conference call and webcast on September 29, 2025, to discuss updates on their nomlabofusp clinical development program for treating Friedreich’s ataxia. The event will cover data from an ongoing long-term open label study. To participate, visit the provided link for the webcast or call in using the provided numbers and conference ID. Larimar focuses on developing treatments for complex rare diseases, with nomlabofusp as their lead compound for Friedreich’s ataxia. For more information, visit their website. The company emphasizes forward-looking statements in their updates, addressing risks and uncertainties in their product development and commercialization efforts.

Read more at GlobeNewswire: Larimar Therapeutics Announces Conference Call on the